New anti-trypanosomal active tetracyclic iridoid isolated from Morinda lucida Benth.

dc.contributor.authorSuzuki, M.
dc.contributor.authorTung, N.H.
dc.contributor.authorKwofie, K.D.
dc.contributor.authorAdegle, R.
dc.contributor.authorAmoa-Bosompem, M.
dc.contributor.authorSakyiamah, M.
dc.contributor.authorAyertey, F.
dc.contributor.authorOwusu, K.B.-A.
dc.contributor.authorTuffour, I.
dc.contributor.authorAtchoglo, P.
dc.contributor.authorFrempong, K.K.
dc.contributor.authorAnyan, W.K.
dc.contributor.authorUto, T.
dc.contributor.authorMorinaga, O.
dc.contributor.authorYamashita, T.
dc.contributor.authorAboagye, F.
dc.contributor.authorAppiah, A.A.
dc.contributor.authorAppiah-Opong, R.
dc.contributor.authorNyarko, A.K.
dc.contributor.authorYamaoka, S.
dc.contributor.authorYamaguchi, Y.
dc.contributor.authorEdoh, D.
dc.contributor.authorKoram, K.
dc.contributor.authorOhta, N.
dc.contributor.authorBoakye, D.A.
dc.contributor.authorAyi, I.
dc.contributor.authorShoyama, Y.
dc.date.accessioned2018-09-17T14:22:16Z
dc.date.available2018-09-17T14:22:16Z
dc.date.issued2015-08
dc.description.abstractHuman African trypanosomiasis (HAT), commonly known as sleeping sickness has remained a serious health problem in many African countries with thousands of new infected cases annually. Chemotherapy, which is the main form of control against HAT has been characterized lately by the viewpoints of toxicity and drug resistance issues. Recently, there have been a lot of emphases on the use of medicinal plants world-wide. Morinda lucida Benth. is one of the most popular medicinal plants widely distributed in Africa and several groups have reported on its anti-protozoa activities. In this study, we have isolated one novel tetracyclic iridoid, named as molucidin, from the CHCl3 fraction of the M. lucida leaves by bioassay-guided fractionation and purification. Molucidin was structurally elucidated by 1H and 13C NMR including HMQC, HMBC, H–H COSY and NOESY resulting in tetracyclic iridoid skeleton, and its absolute configuration was determined. We have further demonstrated that molucidin presented a strong anti-trypanosomal activity, indicating an IC50 value of 1.27 μM. The cytotoxicity study using human normal and cancer cell lines indicated that molucidin exhibited selectivity index (SI) against two normal fibroblasts greater than 4.73. Furthermore, structure–activity relationship (SAR) study was undertaken with molucidin and oregonin, which is identical to anti-trypanosomal active components of Alnus japonica. Overlapping analysis of the lowest energy conformation of molucidin with oregonin suggested a certain similarities of aromatic rings of both oregonin and molucidin. These results contribute to the future drug design studies for HAT.en_US
dc.identifier.otherVolume 25, Issue 15, Pages 3030-3033
dc.identifier.otherhttps://doi.org/10.1016/j.bmcl.2015.05.003
dc.identifier.urihttp://ugspace.ug.edu.gh/handle/123456789/24202
dc.language.isoenen_US
dc.publisherBioorganic & Medicinal Chemistry Lettersen_US
dc.subjectMorinda lucidaen_US
dc.subjectTetracyclic iridoiden_US
dc.subjectMolucidinen_US
dc.subjectAnti-trypanosomal activityen_US
dc.subjectMedicinal plantsen_US
dc.titleNew anti-trypanosomal active tetracyclic iridoid isolated from Morinda lucida Benth.en_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description: